Akari Therapeutics, Plc Accounts Payable
Akari Therapeutics, Plc (AKTX) had Accounts Payable of $9.40 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $9.40M.
- 2026-03-31: Accounts Payable, Current $8.64M.
- 2025-12-31: Accounts Payable, Current $8.77M.
- 2025-09-30: Accounts Payable, Current $10.84M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $9.40M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $8.64M 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $8.77M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $10.84M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $11.61M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $13.07M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $12.41M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $4.78M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $5.47M 8-K · filed 2024-09-06 | $4.69M 10-Q · filed 2024-08-19 |
| 2024-03-31 | $3.21M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.67M 10-K · filed 2025-04-15 | |
| 2023-06-30 | $1.03M 6-K · filed 2023-09-29 | |
| 2022-12-31 | $3.62M 8-K · filed 2024-09-06 | $946.66K 20-F · filed 2023-05-01 |
| 2022-06-30 | $1.63M 6-K · filed 2022-09-27 | |
| 2021-12-31 | $1.79M 20-F · filed 2023-05-01 | |
| 2021-06-30 | $1.69M 6-K · filed 2021-09-22 | |
| 2020-12-31 | $3.38M 20-F · filed 2022-05-16 | |
| 2020-09-30 | $2.41M 20-F · filed 2021-04-21 | |
| 2020-06-30 | $2.19M 20-F · filed 2021-04-21 | |
| 2020-03-31 | $966.06K 20-F · filed 2021-04-21 | |
| 2019-12-31 | $1.23M 20-F · filed 2021-04-21 | |
| 2019-09-30 | $1.32M 20-F · filed 2021-04-21 | |
| 2019-06-30 | $1.48M 20-F · filed 2021-04-21 | |
| 2019-03-31 | $1.76M 20-F · filed 2021-04-21 | |
| 2018-12-31 | $1.59M 20-F · filed 2020-03-31 | |
| 2018-06-30 | $2.00M 6-K · filed 2018-09-27 | |
| 2017-12-31 | $1.97M 20-F · filed 2019-04-23 | |
| 2017-06-30 | $2.84M 6-K · filed 2017-08-10 | |
| 2016-12-31 | $2.21M 20-F · filed 2018-07-18 | |
| 2016-06-30 | $1.92M 6-K · filed 2017-04-14 | |
| 2016-03-31 | $625.37K 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $4.32M 6-K · filed 2017-04-14 | |
| 2015-09-30 | $3.75M 10-Q · filed 2015-11-23 | |
| 2014-12-31 | $555.53K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |